Policy Advisory Board

Key stakeholders with experience in translating research to policy will be integrated and connected through our activities. These stakeholders include integrated healthcare system providers and payers, substance use disorder and health care providers, public and private payers, federal and state policy makers, and the pharmaceutical industry. The Policy Advisory Board represent the perspectives of these stakeholders and will be instrumental in the functioning and operations of the Dissemination and Policy Core. Members of the Policy Advisory Board assist in disseminating policy-relevant findings to key stakeholders.


Mady Chalk, PhD, MSW
Director of the Center on Policy Research and Analysis at the Treatment Research Institute (TRI)

Robert Forman, PhD
Director of Professional Relations and Policy for Alkermes, Inc.

Michael Horberg, MD
Executive Director of Research and Community Benefit of the Mid-Atlantic Permanente Medical Group
Director of the Mid-Atlantic Permanente Research Institute (MAPRI)
Director of HIV/AIDS for Kaiser Permanente

Thomas McLellan, PhD
Co-founder of TRI and an internationally renowned substance abuse researcher
Former Science Advisor and Deputy Director of the White House Office of National Drug Control Policy (ONDCP)

Edmondo J. Robinson, MD, MBA, FACP
Physician-in-chief at Christiana Care’s Wilmington Hospital

Joshua Sharfstein, MD
Associate Dean of Public Health Practice, Johns Hopkins Bloomberg School of Public Health
Former Secretary of the Maryland Department of Health and Mental Hygiene
Former Principal Deputy Commissioner of the U.S Food and Drug Administration

Hyong Un, MD
Chief Psychiatric Officer for Aetna’s Behavioral Health